Market capitalization | $1.39b |
Enterprise Value | $1.43b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.74 |
P/S ratio (TTM) P/S ratio | 1.69 |
P/B ratio (TTM) P/B ratio | 1.90 |
Revenue growth (TTM) Revenue growth | 12.15% |
Revenue (TTM) Revenue | $823.60m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
16 Analysts have issued a Myriad Genetics, Inc. forecast:
16 Analysts have issued a Myriad Genetics, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 824 824 |
12%
12%
|
|
Gross Profit | 527 527 |
14%
14%
|
|
EBITDA | -42 -42 |
50%
50%
|
EBIT (Operating Income) EBIT | -103 -103 |
34%
34%
|
Net Profit | -116 -116 |
58%
58%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual's risk of developing a disease later in life. The Other segment offers products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients; and also includes corporate services such as finance, human resources, legal, and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.
Head office | United States |
CEO | Paul Diaz |
Employees | 2,700 |
Founded | 1991 |
Website | www.myriad.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.